

SCIENTIFIC PANEL ON NUTRITION, NOVEL FOODS AND FOOD ALLERGENS

160th NDA Panel Plenary meeting



27 August 2025

9:00 – 18:00

MINUTES - Agreed on 8 September 2025

Location: Teleconference

Attendees:

- Panel Members:
Montaña Cámara, Jacqueline Castenmiller, Stefaan de Henauw, Karen Ildico Hirsch-Ernst, Ángeles Jos, Inge Mangelsdorf, Breige McNulty, Androniki Naska, Kristina Pentieva, Alfonso Siani, Frank Thies, and Dominique Turck (Chair).
- Hearing Experts¹:
Georges Kass
- European Commission and/or Member States representatives:
Not applicable
- EFSA:
Nutrition & Food Innovation (NIF) Unit: Ana Afonso, Reinhard Ackerl, Océane Albert, Ionut Craciun, Areti Favata, Thibault Fiolet, Andrea Germini, Leng Heng, Marcello Laganaro, Maura Magani, Irene Nuin, Annamaria Rossi, Ariane Titz, Emanuela Turla, Silvia Valtueña Martinez, and Ermolaos Ververis.
- Others:
Not applicable

1. Welcome and apologies for absence

The Chair welcomed the participants.
Apologies were received from Torsten Bohn and Alexandre Maciuk.

2. Adoption of agenda

The agenda was adopted without changes.

3. Declarations of Interest of Panel members

In accordance with EFSA's Policy on Independence² and the Decision of the Executive Director on Competing Interest Management³, EFSA screened the Annual Declarations of Interest filled out by the Panel members invited to the present meeting. No conflicts of interest related to the issues discussed in this meeting have been identified during the screening process. Certain interests were declared orally by one member before the beginning of the WG meeting. For further details on the outcome of the screening of the Oral Declaration of Interest made at the beginning of the meeting, please refer to the Annex.

¹ As defined in Article 34 of the document "Implementing Rule of the Management Board of the European Food Safety Authority laying down the rules on the selection, appointment and operations of the Scientific Committee, Scientific Panels and of their Working Groups":
<https://www.efsa.europa.eu/sites/default/files/paneloperation.pdf>

² https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/independence-policy-2024.pdf

³ https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/decision-ed-on-competing-interest-management-2024.pdf



4. Agreement of the minutes of the 159th NDA Plenary meeting held on 24 – 25 June, in Parma

The [minutes of the 159th Panel plenary meeting](#) were agreed by written procedure on 7 July 2025.

On 10 July 2025, the NDA Panel, having evaluated the data, adopted by written procedure a scientific opinion on the "[safety of lacto-N-tetraose \(LNT\) produced by a derivative strain \(*Escherichia coli* K-12 MG1655 INB LNT 01\) of *E. coli* K-12 MG1655 \(ATCC 700926\) as a NF pursuant to Regulation \(EU\) 2015/2283](#)" ([EFSA-Q-2023-00671](#)).

5. Scientific output submitted for discussion/adoption

5.1 Draft opinion on Beta-glucans from oats and barley and reduction of post-prandial glycaemic responses (HC-2024-23552, [EFSA-Q-2024-00674](#)) Applicant: Pespico International

The Panel reviewed and discussed the draft opinion, and particularly the sections related to the studies submitted for the scientific substantiation of the claimed effect under the new conditions of use proposed by the applicant. The opinion was adopted by the Panel on 27 August, subject to the incorporation of editorial changes. The full text of the scientific opinion will be available in the coming weeks in the EFSA Journal.

5.2 Draft opinion on Calcium sulfate (E516) and reduction in body weight (HC-2024-31891, [EFSA-Q-2025-00138](#)) Applicant: Medicconomics APS

The Panel reviewed and discussed the draft opinion, and particularly the sections related to the characterisation of the food/constituent, the claimed effect, the studies submitted for the scientific substantiation of the claimed effect, and the proposed mechanisms of action. The opinion was adopted by the Panel on 27 August, subject to the incorporation of editorial changes. The full text of the scientific opinion will be available in the coming weeks in the EFSA Journal.

5.3 Draft opinion on Rapeseed protein-fibre concentrate (NF 2022/8650, [EFSA-Q-2023-00160](#)) Applicant: "NapiFeryn BioTech Sp. z o.o."

The Panel reviewed and discussed the draft opinion, and particularly the sections regarding nutritional information, toxicological information, and allergenicity. The opinion was adopted by the Panel on 27 August 2025, subject to the incorporation of editorial changes. The full text of the scientific opinion will be available in the coming weeks in the EFSA Journal.

5.4 Draft opinion on the safety of modification of use of Chuta (NF 2023/16231, [EFSA-Q-2023-00416](#)) Applicant: Chuta Nut GmbH

The item was postponed to the next NDA Plenary meeting of 29-30 September 2025.

5.5 Draft opinion on the safety of the extension of use of pasteurised *Akkermansia muciniphila* (NF 2023-21195; [EFSA-Q-2023-00893](#)) Applicant: The Akkermansia Company SA



The Panel reviewed and discussed the draft opinion, and particularly the sections regarding the proposed uses and use levels and the toxicological information. The opinion was adopted by the Panel on 27 August 2025, subject to the incorporation of editorial changes. The full text of the scientific opinion will be available in the coming weeks in the EFSA Journal.

6. Other scientific topics for information/discussion/endorsement

6.1 Updated statement on the safety of cannabidiol (CBD) as a novel food (EFSA-Q-2025-00218)

The Panel reviewed and discussed the draft of the Updated statement on the safety of CBD, which takes into consideration new literature published between 2021 and 2024, and data submitted by applicants. The discussions focused particularly on the sections regarding the different endpoints, the confirmed data gaps and uncertainties, the benchmark dose (BMD) modelling, and the provisional safe dose of CBD. On 27 August, the draft of the updated statement was endorsed by the Panel for public consultation, subject to the incorporation of editorial changes.

The public consultation will be open from **9 September** to **14 October 2025**. Stakeholders are invited to submit their comments via this [LINK](#).

7. Feedback from the Scientific Committee/ Scientific Panels/EFSA/ EC

Postponed

8. Any other business

None.

9. Next meeting

The next meeting will be held on 29 and 30 September 2025, in Parma.



Annex

Interests and actions resulting from the Oral Declaration of Interest done at the beginning of the meeting

With regard to this meeting, Karen Ildico Hirsch-Ernst declared the following interest: updated annual DoI is currently under evaluation and related to the change in the status of BfR, Federal Institute for Risk Assessment (her employment organisation). In accordance with EFSA's Policy on Independence⁴ and the Decision of the Executive Director on Competing Interest Management⁵, and taking into account the specific matters discussed at the meeting in question, the interest above was not deemed to represent a Conflict of Interest for the expert concerned.

⁴ https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/independence-policy-2024.pdf

⁵ https://www.efsa.europa.eu/sites/default/files/corporate_publications/files/decision-ed-on-competing-interest-management-2024.pdf